[{"id":"714db3ca-404e-4222-9a0f-e2cca6ea14dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT07483567","created_at":"2026-03-28T01:36:25.975Z","updated_at":"2026-03-28T01:36:25.975Z","phase":"Phase 2","brief_title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT07483567","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/30/2026","start_date":" 03/30/2026","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2026-03-19"},{"id":"b8f6cdd3-6953-45e6-a654-0d04207d6f01","acronym":"","url":"https://clinicaltrials.gov/study/NCT07481357","created_at":"2026-03-28T01:39:34.825Z","updated_at":"2026-03-28T01:39:34.825Z","phase":"Phase 1","brief_title":"A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT07481357","lead_sponsor":"Dong-A ST Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 02/01/2026","start_date":" 02/01/2026","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2026-03-18"},{"id":"b0107240-c9ff-4b67-b853-211b0d9cdc8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469774","created_at":"2026-03-28T01:44:13.768Z","updated_at":"2026-03-28T01:44:13.768Z","phase":"Phase 1/2","brief_title":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07469774","lead_sponsor":"Biocity Biopharmaceutics Co., Ltd.","biomarkers":" EGFR • BRAF • ALK • MET • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • ALK • MET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/17/2026","start_date":" 03/17/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2026-03-13"},{"id":"d56691d6-631f-4daa-9d9c-1b3527ec47af","acronym":"SAFE ESO","url":"https://clinicaltrials.gov/study/NCT07205731","created_at":"2025-10-11T01:29:40.189Z","updated_at":"2025-10-11T01:29:40.189Z","phase":"Phase 2","brief_title":"Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma","source_id_and_acronym":"NCT07205731 - SAFE ESO","lead_sponsor":"University Hospital, Clermont-Ferrand","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2025-10-03"},{"id":"a3f2cdb8-5f51-4d49-bdd8-408b76b63c70","acronym":"ZANGEA","url":"https://clinicaltrials.gov/study/NCT07176312","created_at":"2025-09-20T07:08:39.876Z","updated_at":"2025-09-20T07:08:39.876Z","phase":"Phase 2","brief_title":"Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients","source_id_and_acronym":"NCT07176312 - ZANGEA","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • Ziihera (zanidatamab-hrii)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-09-16"},{"id":"8429aef2-3578-430a-8f3c-fc5f753d6982","acronym":"","url":"https://clinicaltrials.gov/study/NCT07161453","created_at":"2025-09-13T08:46:03.641Z","updated_at":"2025-09-13T08:46:03.641Z","phase":"Phase 4","brief_title":"Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology","source_id_and_acronym":"NCT07161453","lead_sponsor":"Liaoning Cancer Hospital \u0026 Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-09-08"},{"id":"716dc364-32b8-4cd4-ad8c-813b9359535b","acronym":"PB-PD1R-SCC","url":"https://clinicaltrials.gov/study/NCT07147361","created_at":"2025-09-07T01:05:27.471Z","updated_at":"2025-09-07T01:05:27.471Z","phase":"","brief_title":"Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma","source_id_and_acronym":"NCT07147361 - PB-PD1R-SCC","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2025-08-29"},{"id":"efd9f946-f015-462e-a89d-d7d3988373c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07149181","created_at":"2025-08-30T13:47:49.395Z","updated_at":"2025-08-30T13:47:49.395Z","phase":"Phase 4","brief_title":"Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery","source_id_and_acronym":"NCT07149181","lead_sponsor":"Liaoning Cancer Hospital \u0026 Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 08/31/2025","start_date":" 08/31/2025","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-08-29"},{"id":"40eafc96-e8a8-4405-abf1-3e7824637479","acronym":"","url":"https://clinicaltrials.gov/study/NCT07132528","created_at":"2025-08-23T13:29:17.809Z","updated_at":"2025-08-23T13:29:17.809Z","phase":"Phase 4","brief_title":"Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer","source_id_and_acronym":"NCT07132528","lead_sponsor":"Liaoning Cancer Hospital \u0026 Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 08/31/2025","start_date":" 08/31/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-08-20"},{"id":"dfadf95a-f23a-4a0a-9690-cd05cb17f698","acronym":"","url":"https://clinicaltrials.gov/study/NCT06979869","created_at":"2025-06-28T16:15:26.907Z","updated_at":"2025-06-28T16:15:26.907Z","phase":"","brief_title":"Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Esophageal Carcinoma","source_id_and_acronym":"NCT06979869","lead_sponsor":"Xijing Hospital","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 05/25/2025","start_date":" 05/25/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-05-20"},{"id":"18709fb5-d496-4979-9052-5f591bc2f04d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06949033","created_at":"2025-06-28T16:10:58.051Z","updated_at":"2025-06-28T16:10:58.051Z","phase":"Phase 3","brief_title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06949033","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 668","initiation":"Initiation: 05/15/2025","start_date":" 05/15/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-29"},{"id":"722a2a86-9fad-4d71-874a-87f0351a5eef","acronym":"","url":"https://clinicaltrials.gov/study/NCT06925243","created_at":"2025-06-28T16:10:56.066Z","updated_at":"2025-06-28T16:10:56.066Z","phase":"Phase 3","brief_title":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06925243","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 682","initiation":"Initiation: 04/15/2025","start_date":" 04/15/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-22"},{"id":"1eccb30a-8ad1-4c26-a948-9dcc1f4fa1f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03832855","created_at":"2021-01-18T18:55:29.583Z","updated_at":"2025-02-25T12:27:07.330Z","phase":"Phase 1","brief_title":"Assessing the Immunogenicity of pING-hHER3FL","source_id_and_acronym":"NCT03832855","lead_sponsor":"Herbert Lyerly","biomarkers":" ERBB3","pipe":" | ","alterations":" ERBB3 expression","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pING-hHER3FL"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-24"},{"id":"0b405f7d-3f61-4823-b79f-2d25bdb0eeb2","acronym":"SGNPDL1V-001","url":"https://clinicaltrials.gov/study/NCT05208762","created_at":"2023-05-26T17:05:40.425Z","updated_at":"2025-02-25T13:49:21.100Z","phase":"Phase 1","brief_title":"A Study of SGN-PDL1V in Advanced Solid Tumors","source_id_and_acronym":"NCT05208762 - SGNPDL1V-001","lead_sponsor":"Seagen Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PF-08046054"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 11/18/2027","primary_completion_date":" 11/18/2027","study_txt":" Completion: 11/17/2028","study_completion_date":" 11/17/2028","last_update_posted":"2025-02-21"},{"id":"488850a4-401a-418b-88e8-32f7b6c5f0dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038578","created_at":"2023-09-15T18:09:55.230Z","updated_at":"2025-02-25T13:41:43.311Z","phase":"Phase 2","brief_title":"A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer","source_id_and_acronym":"NCT06038578","lead_sponsor":"Toray Industries, Inc","biomarkers":" CAPRIN1","pipe":"","alterations":" ","tags":["CAPRIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Cyramza (ramucirumab) • TRK-950"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-21"},{"id":"57288cee-f3b1-4cec-ae85-3fdf330023c7","acronym":"PBC039","url":"https://clinicaltrials.gov/study/NCT05396300","created_at":"2024-04-30T20:56:25.696Z","updated_at":"2025-02-25T13:41:03.634Z","phase":"Phase 1","brief_title":"A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05396300 - PBC039","lead_sponsor":"Weijia Fang, MD","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • C-13-60"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"dc06b6ac-0a69-4fa1-bf0d-291d63c5c2bc","acronym":"HERTHENA-PanTumor01","url":"https://clinicaltrials.gov/study/NCT06172478","created_at":"2023-12-15T19:20:07.848Z","updated_at":"2025-02-25T13:41:58.738Z","phase":"Phase 2","brief_title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06172478 - HERTHENA-PanTumor01","lead_sponsor":"Daiichi Sankyo","biomarkers":" ERBB3","pipe":"","alterations":" ","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 02/26/2024","start_date":" 02/26/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-21"},{"id":"fb5a3d64-2b8f-44c4-84f0-e927e52ab2a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04939051","created_at":"2024-02-29T18:31:43.001Z","updated_at":"2025-02-25T13:35:51.854Z","phase":"Phase 2","brief_title":"Obeticholic Acid for Prevention in Barrett's Esophagus","source_id_and_acronym":"NCT04939051","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FGF19 • SOX2 • CASP3 • FGF • CDX2","pipe":"","alterations":" ","tags":["FGF19 • SOX2 • CASP3 • FGF • CDX2"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/03/2024","start_date":" 01/03/2024","primary_txt":" Primary completion: 09/29/2025","primary_completion_date":" 09/29/2025","study_txt":" Completion: 09/29/2026","study_completion_date":" 09/29/2026","last_update_posted":"2025-02-21"},{"id":"9c255554-467f-443d-b9bf-0883f980d302","acronym":"SGNB6A-001","url":"https://clinicaltrials.gov/study/NCT04389632","created_at":"2021-08-12T17:53:41.583Z","updated_at":"2025-02-25T13:53:17.348Z","phase":"Phase 1","brief_title":"A Study of SGN-B6A in Advanced Solid Tumors","source_id_and_acronym":"NCT04389632 - SGNB6A-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)"],"overall_status":"Recruiting","enrollment":" Enrollment 824","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2025-02-20"},{"id":"b94d3fe3-9040-4df9-8c37-231f34f9f98f","acronym":"POLESTAR","url":"https://clinicaltrials.gov/study/NCT05268510","created_at":"2022-03-07T18:53:55.391Z","updated_at":"2025-02-25T13:54:16.446Z","phase":"Phase 2","brief_title":"Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma","source_id_and_acronym":"NCT05268510 - POLESTAR","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" HER-2 • PD-L1 • CD8 • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine • oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 08/27/2024","primary_completion_date":" 08/27/2024","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-20"},{"id":"bc39ab78-40de-4c87-a343-8cc08b803775","acronym":"PHANTOM","url":"https://clinicaltrials.gov/study/NCT06298916","created_at":"2024-03-07T21:32:59.829Z","updated_at":"2025-02-25T13:56:04.717Z","phase":"Phase 1/2","brief_title":"64Cu-LNTH-1363S in Patients with Sarcoma or Gastrointestinal Tract Cancer","source_id_and_acronym":"NCT06298916 - PHANTOM","lead_sponsor":"Lantheus Medical Imaging","biomarkers":" FAP","pipe":" | ","alterations":" FAP expression","tags":["FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FAP expression"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-20"},{"id":"cb7ed592-cf61-416e-86bf-22b417e0e5af","acronym":"M21-404","url":"https://clinicaltrials.gov/study/NCT05029882","created_at":"2021-09-01T14:52:59.151Z","updated_at":"2025-02-25T13:53:58.746Z","phase":"Phase 1","brief_title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","source_id_and_acronym":"NCT05029882 - M21-404","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • EGFR wild-type","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 520","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-20"},{"id":"308e274e-e2f7-4972-a5fd-9ed7015b2fc2","acronym":"HERIZON-GEA-01","url":"https://clinicaltrials.gov/study/NCT05152147","created_at":"2021-12-09T18:00:29.644Z","updated_at":"2025-02-25T14:02:38.513Z","phase":"Phase 3","brief_title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","source_id_and_acronym":"NCT05152147 - HERIZON-GEA-01","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Ziihera (zanidatamab-hrii)"],"overall_status":"Recruiting","enrollment":" Enrollment 918","initiation":"Initiation: 12/02/2021","start_date":" 12/02/2021","primary_txt":" Primary completion: 05/15/2025","primary_completion_date":" 05/15/2025","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2025-02-19"},{"id":"3875d166-2701-445e-aa30-32ca8986f0a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03092518","created_at":"2021-01-18T15:14:06.092Z","updated_at":"2025-02-25T14:01:14.625Z","phase":"Phase 2","brief_title":"Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology","source_id_and_acronym":"NCT03092518","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • mitomycin • Jelmyto (mitomycin urothelial gel)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/05/2017","start_date":" 06/05/2017","primary_txt":" Primary completion: 04/05/2024","primary_completion_date":" 04/05/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2025-02-19"}]